4.5 Review

Epstein-Barr virus and multiple sclerosis. From evidence to therapeutic strategies

Journal

JOURNAL OF THE NEUROLOGICAL SCIENCES
Volume 361, Issue -, Pages 213-219

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jns.2016.01.013

Keywords

Multiple sclerosis; Epstein-Barr virus; Human endogenous retroviruses; B-cell; CD20

Funding

  1. Basque Country Foundation for Health Innovation and Research
  2. Bayer-Schering
  3. Biogen Idec
  4. Merck Seron
  5. Novartis
  6. UCB
  7. Almirall
  8. Teva

Ask authors/readers for more resources

Multiple sclerosis is caused by a complex interaction between genetic predisposition and environmental factors. Epstein Barr virus (EBV) is an environmental risk factor that is strongly related to multiple sclerosis (MS), since EBV seropositivity is linked to a significant risk of developing MS. EBV may be involved in the pathogenesis of the disease and it is possibly a prerequisite for the development of MS. EBV infection persists in B-cells during the lifetime of the host and can modulate their function. In addition, MS patients might have a deficient capacity to eliminate latent EBV infection in the central nervous system and this would promote the accumulation of infected B cells. Several mechanisms of pathogenesis, including a direct and indirect function of infected B cells, have been postulated in inflammation and neurodegeneration. A relationship between EBV and human endogenous retroviruses in the pathogenesis of MS has also been reported. If EBV is important in the pathogenesis of MS, different therapeutic strategies seem possible for MS treatment. (C) 2016 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available